期刊文献+

人4-1BBL胞外区/抗CD20融合蛋白的构建和表达 被引量:6

Construction and expression of human 4-1BBL/anti-CD20 fusion protein
下载PDF
导出
摘要 目的:构建和表达人4-1BBL胞外区/抗CD20双功能融合蛋白,并测定该融合蛋白的生物学活性。方法:采用PCR和ovelap PCR方法构建人4-1BBL胞外区/抗CD20双功能融合蛋白,并用双脱氧终止法测定DNA序列;采用亲和层析法纯化该产物,并用150g/L SDS-PAGE和Western blot鉴定纯化产物;采用FACS法鉴定纯化产物与靶细胞的结合活性。结果:DNA序列测定结果表明:人4-1BBL胞外区/抗CD20双功能融合蛋白已构建成功,表达可溶性产物的产量达4mg/L以上,具有与Raji细胞(CD20+)和A549(4-1BB+)细胞结合的活性。结论:利用融合蛋白形式,首次成功地构建了人4-1BBL胞外区/抗CD20融合蛋白,并获得较高表达。表达产物具有与相应2个靶抗原结合的活性。 AIM: To construct and express human 4- 1 BBL./anti-CD20 bispecific fusion protein and identify its biological activity. METHODS: PCR and overlapping PCR were used to construct human 4-1BBL/anti-CD20 bispeciflc fusion protein. DNA sequencing was performed by the terminus of the fusion protein nucleotide. The product was purified by affinity chromatography and analyzed by Western blot and its antigen-binding activity was examined by FACS. RESULTS: The data of DNA sequence showed that human 4-1BBL/anti-CD20 bispecific fusion protein was correct. The fusion protein was recovered in high yield ( up to 4 mg/L) after E-tag purification and predominantly (90%) as a dimer. The fusion protein could bind to Raji cells ( CD20^+ ) and A.549 cells ( 4-1BB^+ ), respectively. CONCLUSION: The human 4-1BBL./anti-CD20 bispecific fusion protein with high level expression was successfully obtained and could bind to Raji cells and A549 cells.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2008年第6期543-545,549,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金资助项目(30572203 30570772) 山东省自然科学基金资助项目(Q2006C02)
关键词 4-1BBL CD20 融合蛋白 免疫治疗 4-1BBL CD20 fusion frotein immunotherapy
  • 相关文献

参考文献9

  • 1Cochlovius B, Kipriyanov SM, Stassar M J, et al. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells [J]. J Immunol, 2000, 165(2) : 888 -895.
  • 2Xiong D, Xu Y, Liu H, et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody [J]. Cancer Lett, 2002, 177(1) : 29 -39.
  • 3Gao Y, Xiong D, Yang M, et al. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody[ J] . Leukemia, 2004, 18(3) : 513 -520.
  • 4姜文国,熊冬生,邵晓枫,王金宏,许元富,刘芳,郭红星,朱祯平,杨纯正.人4-1BBL胞外区基因的克隆与表达研究[J].生物工程学报,2005,21(5):703-707. 被引量:7
  • 5Campbell AM. Fusion procedures [ A ] : Burden RH, Knippenberg PH: Laboratory techniques in biochemistry and molecular biology: Monoclonal antibody technology [ M ]. Elsevier Amsterdam, 1984:120 -134.
  • 6Bukczynski J, Wen T, Watts TH. Costimulation of human CD28^ - T cells by 4-1BB ligand [ J ]. Eur J Immunol, 2003, 33 ( 2 ) : 446 - 454.
  • 7Cooper D, Bansal Pakala P, Croft M. 4-1BB (CD137) controls the clonal expansion and survival of CD8^+ T cells in vivo but does not contribute to the development of cytotoxicity [ J ]. Eur J Immunol, 2002, 32 (2) : 522 - 529.
  • 8Holliger P, Manzke O, Span M, et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti- CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins[J]. Cancer Res, 1999, 59 (12) : 2909 -2916.
  • 9Cochlovius B, Kipriyanov SM, Stassar M J, et al. Cure of Burkitt' s lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation[ J]. Cancer Res, 2000, 60( 16): 4336-4341.

二级参考文献9

  • 1Schwarz H, Valbracht J, Tuckwell J et al. ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages.Blood, 1995, 85(4): 1043 - 1052
  • 2Bukczynski J, Wen T, Watts TH. Costimulation of human CD28- T cells by 4-1BB ligand. Eur J Immunol, 2003,33(2) :446 - 454
  • 3Myers L, Takahashi C, Mittler RS et al. Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc Natl Acad Sci USA, 2003,100(9) :5348 - 5353
  • 4Melero I, Bach N, Hellstrom KE et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand:synergy with the CD28 co-stimulatory pathway. Eur J Immunol,1998,28(3): 1116 - 1121
  • 5Li Q, Carr A, Ito F et al. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res, 2003, 63(10) :2546 - 2552
  • 6Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A et al. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med, 2002,8(4) :343 - 348
  • 7Martinet O, Divino CM, Zang Y et al. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther, 2002,9(12) :786 - 792
  • 8高瀛岱,熊冬生,许元富,彭晖,邵晓枫,杨纯正,朱祯平.抗CD3/抗Pgp微型双功能抗体的构建和表达[J].生物工程学报,2003,19(4):444-449. 被引量:18
  • 9刘银星,熊冬生,范冬梅,邵晓枫,许元富,朱祯平,杨纯正.抗CD20嵌合抗体片段Fab′突变体的表达和活性研究[J].生物工程学报,2003,19(3):272-276. 被引量:5

共引文献6

同被引文献45

  • 1郁子扬,张立煌.细胞因子重组融合蛋白研究进展[J].中国肿瘤生物治疗杂志,2004,11(2):148-150. 被引量:2
  • 2王玉刚,沈倍奋.CD20抗原及治疗性抗CD20抗体[J].中国肿瘤生物治疗杂志,2005,12(1):76-79. 被引量:10
  • 3姜文国,熊冬生,邵晓枫,王金宏,许元富,刘芳,郭红星,朱祯平,杨纯正.人4-1BBL胞外区基因的克隆与表达研究[J].生物工程学报,2005,21(5):703-707. 被引量:7
  • 4杨登科,靳风烁,张勇.Ag85B/IL-2融合蛋白在体外对PBMC增殖及Th1型细胞因子分泌的影响[J].医学临床研究,2006,23(2):181-183. 被引量:5
  • 5Junji Uchidal,Youngkyun Lee,Minoru Hasegawa,et al.Mouse CD20 expression and function[J].International Immunology,2004,16(1):119-129.
  • 6Arzoo K,Sadeghi S,Liebman HA.Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)[J].Ann Rheum Dis online,2002,61:922-924.
  • 7Jubala CM,Wojcieszyn JW,Valli VEO,et al.CD20 expression in normal canine B cells and in canine non-hodgkin lymphoma[J].Vet Pathol,2005,42(4):468-476.
  • 8George Z,Rassidakis L,Jeffrey Medeiros,et al.CD20 expression in hodgkin and reed-sternberg cells of classical hodgkin's disease:associations with presenting features and clinical outcome[J].JCO,2002,20(5):1278-1287.
  • 9Cheson BD.Radioimmunotherapy of non-Hodgkin lymphomas[J].Blood,2003,101(2):391-396.
  • 10Jessica L,Teeling,Ruth R,et al.Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas[J].Blood,2004,104(6):1793-1800.

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部